In a study published in Cell, a research team led by Zhu Shujia from the Center for Excellence in Brain Science and ...

In this study, recently published in Alzheimer's & Dementia, the authors investigated NMDA (N-methyl-D-aspartate receptors) receptors due to their importance in synaptic transmission and their ...

The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced that it has received a U.S. patent for the treatment. AV-101 (4-Cl-KYN) is ...

Vistagen (VTGN) announced that the U.S. Patent and Trademark Office or USPTO, granted a patent to the company for its oral non-opioid product ...

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, ...

This is when antibodies produced by the immune system attack the brain’s own proteins, in this case its NMDA receptors. This receptor is involved in learning and memory, therefore sufferers ...

Although they produce opposite effects on synaptic excitability, both LTP and LTD can occur at the same synapse in response to different patterns of activation of NMDA (N-methyl-D-aspartate ...